Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Software update – AxIS 2.1
AxIS 2.1 is Axion’s new software platform for MEA data acquisition and analysis. Featuring enhanced, integrated cardiac and neural analysis, faster data processing, and plate maps to record and view well treatments, AxIS 2.1 provides significant new functionality that will continue to empower your MEA experiments.
June 10th Webinar – “GFP+ Motor Neurons: Development and in-vitro Functional Assessment”
Wednesday June 10th, 11:30 AM EDT
Hosted by ArunA Biomedical
After an introduction from ArunA Biomedical about their motoroneuron products, Axion scientists will share our experiences working with these cells – cell culture, evaluation of network activity over numerous days in culture, and results from treatment with various compounds.
Update: to view a recording of the webinar, please click here – Play recording